Jesus G Berdeja

22PUBLICATIONS
141CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyClinical social work practiceApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (22)

|Jul 22, 2026
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

|Jun 03, 2026
Arlocabtagene autoleucel: a GPRC5D-targeted CAR T-cell therapy for heavily pretreated relapsed/refractory multiple myeloma.

|Apr 14, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Doris K Hansen, Danai Dima, Hira Mian

|Jan 21, 2026
Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Melissa Alsina, Nina Shah, Sundar Jagannath

|Jun 03, 2025
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.

Sundar Jagannath, Thomas G Martin, Yi Lin

|Jan 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.

Luciano J Costa, Rahul Banerjee, Hira Mian

Pageof 4

Frequent Collaborators

7 joint publications

Sundar Jagannath

6 joint publications

Saad Z Usmani

6 joint publications

Yi Lin

4 joint publications

David Siegel